All Stories

  1. The Kinetics and Interplay of Thrombin Inhibition by Four Plasma Protease Inhibitors
  2. Modelling the effects of 4-factor prothrombin complex concentrate for the management of factor Xa-associated bleeding
  3. Emicizumab promotes factor Xa generation on endothelial cells
  4. Ultrasoft platelet-like particles stop bleeding in rodent and porcine models of trauma
  5. Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants
  6. Inhalation of an RNA aptamer that selectively binds extracellular histones protects from acute lung injury
  7. Thrombin generation and implications for hemophilia therapies: A narrative review
  8. Analytical Validation and Quality Control/Quality Assurance Practices for Improved Rigor and Reproducibility of Biochemical Assays in Orthopaedic Research
  9. A commentary on “A rapid, sensitive and specific assay to measure TF activity based on chromogenic determination of thrombin generation”
  10. Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors
  11. Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding
  12. Trauma-induced coagulopathy
  13. Cell-Mediated Hemostasis
  14. EPCR knockout: inflaming the discussion
  15. A unique protein kinase C-dependent pathway for tissue factor downregulation in pericytes
  16. Regulation of Hemostasis and Thrombosis
  17. The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
  18. The next best thing in factor VIIa
  19. Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity
  20. The Tissue Factor Pathway and Wound Healing
  21. Differentiating between cold agglutinins and rouleaux: a case series of seven patients
  22. Impact of Non–Vitamin K Antagonist Oral Anticoagulants From a Basic Science PerspectiveHighlights
  23. Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis
  24. No association between donor age and recipient outcomes: transfusion of plasma in patients undergoing coronary artery bypass grafting surgery
  25. An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model
  26. Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate
  27. Cell-Mediated Hemostasis
  28. Coated platelet assay: a feasible approach to a complicated science
  29. Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?
  30. Coagulation in Liver Disease
  31. Novel oral anticoagulants and reversal agents: Considerations for clinical development
  32. Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate
  33. Fibrinogen-Coated Nanospheres Prevent Thrombocytopenia-Related Bleeding
  34. 161: Effect of antifibrinolytic drugs on in vitro clot formation among peripartum women
  35. Reversing targeted oral anticoagulants
  36. Hemostasis: Old System, New Players, New Directions
  37. A mouse bleeding model to study oral anticoagulants
  38. Engineering a new generation of hemostatic agents: highlights of the Scientific Session on Hemostasis at the 2013 meeting of the American Society of Hematology
  39. Theories of Blood Coagulation: Basic Concepts and Recent Updates
  40. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
  41. Progressive improvement in wound healing with increased therapy in haemophilia B mice
  42. Superactivated Platelets: Thrombus Regulators, Thrombin Generators, and Potential Clinical Targets
  43. Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels
  44. Practical coagulation for the blood banker
  45. Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity
  46. Mechanisms and monitoring of bypassing agent therapy
  47. The clotting system - a major player in wound healing
  48. Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond
  49. Hemostatic properties of the FVIIa analog NN1731
  50. The multiple roles of tissue factor in wound healing
  51. Hypothesis: Hyperhomocysteinemia is an indicator of oxidant stress
  52. Homocysteinylated fibrinogen forms disulfide-linked complexes with albumin
  53. Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity
  54. Prophylactic correction of the international normalized ratio in neurosurgery: a brief review of a brief literature
  55. Editorial: International normalized ratio
  56. Inflammation does not predispose to bleeding in hemophilia
  57. Heparins: Clinical Use and Laboratory Monitoring
  58. Wound healing in haemophilia - breaking the vicious cycle
  59. Wound healing in hemophilia B mice and low tissue factor mice
  60. Platelet binding and activity of recombinant factor VIIa
  61. Regulation of Hemostasis and Thrombosis
  62. Contributors
  63. Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study
  64. The Influence of Hemophilia on Wound Healing.
  65. Platelet functions beyond hemostasis
  66. Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin
  67. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation
  68. Tissue Factor in Brain Is Not Saturated With Factor VIIa: Implications for Factor VIIa Dosing in Intracerebral Hemorrhage
  69. Celecoxib does not delay cutaneous wound healing in haemophilia B mice
  70. The Coagulation Cascade in Cirrhosis
  71. Dysregulation of Hemostasis by Cancer
  72. FVIIa: you've come a long way, baby!
  73. Animal models of bleeding and tissue repair
  74. Alterations of Fibrinogen Structure in Human Disease
  75. Some things I thought I knew about tissue factor that turn out to be wrong
  76. Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia
  77. Hypercoagulation and thrombophilia in liver disease
  78. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B
  79. Tissue factor around dermal vessels has bound factor VII in the absence of injury
  80. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease
  81. Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes
  82. Coagulation 2006: A Modern View of Hemostasis
  83. Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia
  84. Fathers of modern coagulation
  85. Cutaneous wound healing is impaired in hemophilia B
  86. Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs
  87. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia
  88. A Cell-Based Model of Thrombin Generation
  89. Modification of Fibrinogen by Homocysteine Thiolactone Increases Resistance to Fibrinolysis:  A Potential Mechanism of the Thrombotic Tendency in Hyperhomocysteinemia †
  90. Why Are Young College Women Not Using Condoms? Their Perceived Risk, Drug Use, and Developmental Vulnerability May Provide Important Clues to Sexual Risk
  91. What Does It Take to Make the Perfect Clot?
  92. Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management
  93. High dose factor VIIa improves clot structure and stability in a model of haemophilia B
  94. Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft
  95. Platelet Heterogeneity: Variation in Coagulation Complexes on Platelet Subpopulations
  96. One more way that mice and men are different
  97. Rethinking the Coagulation Cascade
  98. The Cellular Basis of Traumatic Bleeding
  99. New Concepts in Managing Catastrophic Bleeding: A Combat Perspective
  100. A Systematic Evaluation of the Effect of Temperature on Coagulation Enzyme Activity and Platelet Function
  101. UNDERSTANDING AND MANAGING COAGULOPATHIC BLEEDING
  102. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system
  103. Differences in the metabolic response to exogenous homocysteine in juvenile and adult rabbits
  104. Safety profile of recombinant factor VIIa
  105. The Potential Role of Factor VIIa in Transfusion Medicine
  106. Laboratory Monitoring of High-Dose Factor VIIa Therapy
  107. The Effect of Temperature and pH on the Activity of Factor VIIa: Implications for the Efficacy of High-Dose Factor VIIa in Hypothermic and Acidotic Patients
  108. Localization of heparin cofactor II in injured human skin: a potential role in wound healing
  109. A cell-based model of coagulation and the role of factor VIIa
  110. Remodeling the Blood Coagulation Cascade
  111. Protease-Activated Receptor-2 Signaling Triggers Dendritic Cell Development
  112. New Insights into the Coagulation System and Implications for New Therapeutic Options with Recombinant Factor VIIa
  113. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk
  114. Expanding uses of high-dose factor VIIa
  115. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia
  116. The action of high-dose factor Vlla (FVIIa) in a cell-based model of hemostasis
  117. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis
  118. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis
  119. Analyzing fibrin clot structure using a microplate reader
  120. Platelets and Thrombin Generation
  121. Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces
  122. FLT3 internal tandem duplication mutations are rare in agnogenic myeloid metaplasia
  123. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo
  124. Coagulation Factor Interaction with Platelets
  125. Generation of Species Cross-reactive Aptamers Using “Toggle” SELEX
  126. Exposure of Mice to Topical Bovine Thrombin Induces Systemic Autoimmunity
  127. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis
  128. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system
  129. Hemophilia Care in the New Millennium
  130. Inhibition of human and pig thrombin by a high-affinity nuclease-resistant RNA aptamer
  131. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations
  132. Deencryption of Cellular Tissue Factor Is Independent of Its Cytoplasmic Domain
  133. Platelets induce sinusoidal endothelial cell apoptosis upon reperfusion of the cold ischemic rat liver
  134. The Factor VII-Platelet Interplay: Effectiveness of Recombinant Factor VIIa in the Treatment of Bleeding in Severe Thrombocytopathia
  135. Links Between the Immune and Coagulation Systems: How Do "Antiphospholipid Antibodies" Cause Thrombosis?
  136. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations
  137. Platelets from Thrombocytopenic Ponies Acutely Infected with Equine Infectious Anemia Virus Are Activated in Vivo and Hypofunctional
  138. Chemistry and Biology of Serpins Edited by Frank C. Church, Dennis D. Cunningham, David Ginsburg, Maureane Hoffman, Stuart R. Stone, and Douglas M. Tollefsen. Plenum Press:  New York. 1997. xvii + 358 pp. $95.00. ISBN 0-306-45698-2.
  139. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer
  140. Platelet activity of high-dose factor VIIa is independent of tissue factor
  141. From antiphospholipid syndrome to antibody-mediated thrombosis
  142. Chemistry and Biology of Serpins
  143. Variability in platelet procoagulant activity in healthy volunteers
  144. Culturing unactivated monocytes
  145. Cellular Interactions in Hemostasis
  146. Thrombin Enhances Monocyte Secretion of Tumor Necrosis Factor and Interleukin-1 Beta By Two Distinct Mechanisms
  147. The Monocyte Monolayer Assay: A Noninvasive Technique for Predicting the Severity of in Utero Hemolysis
  148. Platelet procoagulant complex assembly in a tissue factor-initiated system
  149. Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: An aid in assessing marrow recovery
  150. Heparin cofactor II and thrombin
  151. Platelets contain releasable coagulation factor IX antigen
  152. Platelets contain releasable coagulation factor IX antigen
  153. Platelet activation in patients with thrombotic thrombocytopenic purpura
  154. A Rapid Method to Isolate Platelets from Human Blood by Density Gradient Centrifugation
  155. The effects of heparin cofactor II-derived chemotaxins on neutrophil actin conformation and cyclic AMP levels
  156. Antibody-Coated Erythrocytes Induce Secretion of Tumor Necrosis Factor by Human Monocytes: A Mechanism for the Production of Fever by Incompatible Transfusions
  157. The Effect of Alpha2Macroglobulin-Proteinase Complexes on Macrophage IA Expression in Vivo
  158. PDGF-stimulated fibroblast proliferation is enhanced synergistically by receptor-recognized ?2-Macroglobulin
  159. Variability in the Fibrinogen and Von Willebrand Factor Content of Cryoprecipitate: Implications for Reducing Donor Exposure
  160. Effect of interferon-γ and human α2-macroglobulin on peritoneal macrophage morphology and Ia antigen expression
  161. Production of chemotactic peptides by neutrophil degradation of heparin cofactor II
  162. Comparison of the effects of IL-1α and TNF-α on phagocyte accumulation and murine antibacterial immunity
  163. Alpha-Macroglobulin Secreted by Alveolar Macrophages Serves as a Binding Protein for a Macrophage-derived Homologue of Platelet-derived Growth Factor
  164. α 2Macroglobulin-proteinase complexes stimulate prostaglandin E2 synthesis by peritoneal macrophages
  165. Reduced trypsin-binding capacity of α2-macroglobulin in the peritoneal fluid of women with endometriosis: possible relevance to alterations in macrophase function**Supported by the Career Development Program of the Veterans Administration (M.H.); the J...
  166. The Effect of Fibrin Polymerization Inhibitors on Quantitative Measurements of Plasma Fibrinogen
  167. The macrophage-mediated regulation of hepatocyte synthesis of antithrombin III and α1-proteinase inhibitor
  168. α2-macroglobulin ‘fast’ forms inhibit superoxide production by activated macrophages
  169. Effect of cyclooxygenase inhibitors and protease inhibitors on phorbol-induced stimulation of oxygen consumption and superoxide production by rat pulmonary macrophages
  170. Production of superoxide anion by an nadph-oxidase from rat pulmonary macrophages
  171. Changes in Oxygen Consumption and Phagocytosis in Rat Pulmonary Macrophages Related to Animal Maturation
  172. Adaptation to hyperoxia in the neonatal rat: Kinetic parameters of the oxygen-mediated induction of lung superoxide dismutases, catalase and glutathione peroxidase